TWI683807B - 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 - Google Patents

作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 Download PDF

Info

Publication number
TWI683807B
TWI683807B TW104129876A TW104129876A TWI683807B TW I683807 B TWI683807 B TW I683807B TW 104129876 A TW104129876 A TW 104129876A TW 104129876 A TW104129876 A TW 104129876A TW I683807 B TWI683807 B TW I683807B
Authority
TW
Taiwan
Prior art keywords
compound
formula
weight
cancer
ethoxy
Prior art date
Application number
TW104129876A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625534A (en
Inventor
麥可 迪麥提諾
關慧萍
Original Assignee
英商葛蘭素史克智慧財產發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商葛蘭素史克智慧財產發展有限公司 filed Critical 英商葛蘭素史克智慧財產發展有限公司
Publication of TW201625534A publication Critical patent/TW201625534A/zh
Application granted granted Critical
Publication of TWI683807B publication Critical patent/TWI683807B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW104129876A 2014-09-10 2015-09-10 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 TWI683807B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2014086197 2014-09-10
WOPCT/CN2014/086197 2014-09-10
WOPCT/CN2015/086995 2015-08-14
CN2015086995 2015-08-14

Publications (2)

Publication Number Publication Date
TW201625534A TW201625534A (en) 2016-07-16
TWI683807B true TWI683807B (zh) 2020-02-01

Family

ID=54186249

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104129876A TWI683807B (zh) 2014-09-10 2015-09-10 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物

Country Status (36)

Country Link
US (4) US9918974B2 (OSRAM)
EP (2) EP3191450B1 (OSRAM)
JP (2) JP6538154B2 (OSRAM)
KR (1) KR20170045350A (OSRAM)
CN (1) CN107074768B (OSRAM)
AU (1) AU2015313841B2 (OSRAM)
BR (1) BR112017004900A2 (OSRAM)
CA (1) CA2960768A1 (OSRAM)
CL (1) CL2017000588A1 (OSRAM)
CO (1) CO2017002273A2 (OSRAM)
CR (1) CR20170093A (OSRAM)
CY (1) CY1121661T1 (OSRAM)
DK (1) DK3191450T3 (OSRAM)
DO (1) DOP2017000059A (OSRAM)
EA (1) EA033544B1 (OSRAM)
ES (2) ES2816453T3 (OSRAM)
HR (1) HRP20190815T1 (OSRAM)
HU (1) HUE044604T2 (OSRAM)
IL (1) IL250908B (OSRAM)
LT (1) LT3191450T (OSRAM)
MA (1) MA40581A (OSRAM)
ME (1) ME03432B (OSRAM)
MX (1) MX373863B (OSRAM)
MY (1) MY181913A (OSRAM)
PE (1) PE20170705A1 (OSRAM)
PH (1) PH12017500425B1 (OSRAM)
PL (1) PL3191450T3 (OSRAM)
PT (1) PT3191450T (OSRAM)
RS (1) RS58813B1 (OSRAM)
SG (1) SG11201701694QA (OSRAM)
SI (1) SI3191450T1 (OSRAM)
SM (1) SMT201900304T1 (OSRAM)
TW (1) TWI683807B (OSRAM)
UA (1) UA122213C2 (OSRAM)
UY (1) UY36293A (OSRAM)
WO (1) WO2016038552A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
PT3191450T (pt) 2014-09-10 2019-05-29 Glaxosmithkline Ip Dev Ltd Derivados de piridona como inibidores da quinase rearranjada durante a transfecção (ret)
EA032030B1 (ru) 2014-09-10 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110891573A (zh) 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN115803316B (zh) * 2020-07-23 2024-12-06 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
AU2023329563A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
SK1812002A3 (en) 1999-08-12 2003-02-04 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
JPWO2004024694A1 (ja) 2002-09-10 2006-01-05 杏林製薬株式会社 ４−置換アリール−５−ヒドロキシイソキノリノン誘導体
JP2007503393A (ja) 2003-08-22 2007-02-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｃｏｐｄ及び肺高血圧の治療方法
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
DK1836169T5 (da) * 2004-12-28 2023-10-09 Atnx Spv Llc Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
DK2041071T3 (da) 2006-06-29 2014-09-01 Kinex Pharmaceuticals Llc Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
JP5568304B2 (ja) * 2006-09-15 2014-08-06 タイロジェネクス，インコーポレイテッド キナーゼ阻害剤化合物
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
PT2970191T (pt) 2013-03-15 2017-03-23 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inibidores da quinase rearranjada durante transfecção(ret)
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
PT3191450T (pt) * 2014-09-10 2019-05-29 Glaxosmithkline Ip Dev Ltd Derivados de piridona como inibidores da quinase rearranjada durante a transfecção (ret)
EA032030B1 (ru) 2014-09-10 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors

Also Published As

Publication number Publication date
CA2960768A1 (en) 2016-03-17
CN107074768B (zh) 2019-12-10
RS58813B1 (sr) 2019-07-31
ES2725704T3 (es) 2019-09-26
MY181913A (en) 2021-01-14
PH12017500425A1 (en) 2017-07-31
JP6728447B2 (ja) 2020-07-22
WO2016038552A1 (en) 2016-03-17
EA033544B1 (ru) 2019-10-31
EA201790546A1 (ru) 2017-07-31
HRP20190815T1 (hr) 2019-07-12
EP3191450B1 (en) 2019-04-10
CY1121661T1 (el) 2020-07-31
MX2017003114A (es) 2017-11-15
HUE044604T2 (hu) 2019-11-28
CO2017002273A2 (es) 2017-06-20
PE20170705A1 (es) 2017-05-21
TW201625534A (en) 2016-07-16
UA122213C2 (uk) 2020-10-12
DOP2017000059A (es) 2017-03-31
ME03432B (me) 2020-01-20
US20170340617A1 (en) 2017-11-30
UY36293A (es) 2016-04-01
CL2017000588A1 (es) 2017-10-06
CN107074768A (zh) 2017-08-18
US20190247382A1 (en) 2019-08-15
US10292975B2 (en) 2019-05-21
AU2015313841B2 (en) 2018-03-08
PT3191450T (pt) 2019-05-29
US9918974B2 (en) 2018-03-20
BR112017004900A2 (pt) 2017-12-12
MA40581A (fr) 2019-04-10
JP2019163316A (ja) 2019-09-26
EP3517526B1 (en) 2020-08-19
EP3517526A1 (en) 2019-07-31
JP6538154B2 (ja) 2019-07-03
CR20170093A (es) 2017-07-17
IL250908B (en) 2020-11-30
PH12017500425B1 (en) 2017-07-31
IL250908A0 (en) 2017-04-30
KR20170045350A (ko) 2017-04-26
MX373863B (es) 2020-03-26
EP3191450A1 (en) 2017-07-19
SI3191450T1 (sl) 2019-07-31
LT3191450T (lt) 2019-06-10
SG11201701694QA (en) 2017-04-27
US10111866B2 (en) 2018-10-30
ES2816453T3 (es) 2021-04-05
US20180147194A1 (en) 2018-05-31
JP2017527578A (ja) 2017-09-21
US10709695B2 (en) 2020-07-14
DK3191450T3 (da) 2019-05-20
AU2015313841A1 (en) 2017-03-23
US20190022078A1 (en) 2019-01-24
SMT201900304T1 (it) 2019-07-11
PL3191450T3 (pl) 2019-08-30

Similar Documents

Publication Publication Date Title
TWI683807B (zh) 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物
CN109745316B (zh) 用于治疗癌症的联合治疗
JP5864545B2 (ja) インドール
ES2931316T3 (es) Forma salina para la inhibición de EZH2
WO2017145050A1 (en) Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
EP2970191B1 (en) Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
TWI623533B (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
CN116368130A (zh) 杂环化合物及其用途
EA021927B1 (ru) 2-[(5-хлор-2-{[3-метил-1-(1-метилэтил)-1н-пиразол-5-ил]амино}-4-пиридинил)амино]-n-(метилокси)бензамид в качестве ингибиторов fak и содержащая его фармацевтическая композиция
TW201041872A (en) Amino ester derivatives, salts thereof and methods of use
JP6122877B2 (ja) ユビキチン活性化酵素のピラゾロピリミジニル阻害剤
JP6816041B2 (ja) Ｚｅｓｔｅホモログ２エンハンサー阻害剤
JP2015508775A5 (OSRAM)
CN116917273A (zh) 作为dnmt1抑制剂的经取代的吡啶
HK1237341A1 (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
HK1237341B (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees